Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood

Akiko Eguchi, Raul G. Lazaro, Jiaohong Wang, Jihoon Kim, Davide Povero, Brandon Willliams, Samuel B. Ho, Peter Stärkel, Bernd Schnabl, Lucila Ohno‐Machado, Hidekazu Tsukamoto, Ariel E. Feldstein – 17 September 2016 – Extracellular vesicles (EVs) released during cell stress, or demise, can contain a barcode of the cell origin, including specific microRNAs (miRNAs). Here, we tested the hypothesis that during early alcoholic steatohepatitis (ASH) development, hepatocytes (HCs) release EVs with an miRNA signature that can be measured in circulation.

Octamer 4/microRNA‐1246 signaling axis drives Wnt/β‐catenin activation in liver cancer stem cells

Stella Chai, Kai‐Yu Ng, Man Tong, Eunice Y. Lau, Terence K. Lee, Kwok Wah Chan, Yun‐Fei Yuan, Tan‐To Cheung, Siu‐Tim Cheung, Xiao‐Qi Wang, Nathalie Wong, Chung‐Mau Lo, Kwan Man, Xin‐Yuan Guan, Stephanie Ma – 17 September 2016 – Wnt/β‐catenin signaling is activated in CD133 liver cancer stem cells (CSCs), a subset of cells known to be a root of tumor recurrence and therapy resistance in hepatocellular carcinoma (HCC). However, the regulatory mechanism of this pathway in CSCs remains unclear.

Effects of kinsenoside, a potential immunosuppressive drug for autoimmune hepatitis, on dendritic cells/CD8+T cells communication in mice

Ming Xiang, Tingting Liu, Wanyue Tan, Hongyu Ren, Hua Li, Junjun Liu, Hui Cao, Qi Cheng, Xiulan Liu, Hucheng Zhu, Yali Tuo, Jianping Wang, Yonghui Zhang – 17 September 2016 – The central purpose of this study was to investigate therapeutic effects of the botanical derivative, kinsenoside (KD), in experimental autoimmune hepatitis (AIH).

Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The “Anticipate” study

Juan G. Abraldes, Christophe Bureau, Horia Stefanescu, Salvador Augustin, Michael Ney, Hélène Blasco, Bogdan Procopet, Jaime Bosch, Joan Genesca, Annalisa Berzigotti, for the Anticipate Investigators – 17 September 2016 – In patients with compensated advanced chronic liver disease (cACLD), the presence of clinically significant portal hypertension (CSPH) and varices needing treatment (VNT) bears prognostic and therapeutic implications. Our aim was to develop noninvasive tests‐based risk prediction models to provide a point‐of‐care risk assessment of cACLD patients.

Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in mice‡

Kelly McDaniel, Fanyin Meng, Nan Wu, Keisaku Sato, Julie Venter, Francesca Bernuzzi, Pietro Invernizzi, Tianhao Zhou, Konstantina Kyritsi, Ying Wan, Qiaobing Huang, Paolo Onori, Heather Francis, Eugenio Gaudio, Shannon Glaser, Gianfranco Alpini – 17 September 2016 – Biliary‐committed progenitor cells (small mouse cholangiocytes; SMCCs) from small bile ducts are more resistant to hepatobiliary injury than large mouse cholangiocytes (LGCCs) from large bile ducts.

Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study

Marianne Martinello, Edward Gane, Margaret Hellard, Joe Sasadeusz, David Shaw, Kathy Petoumenos, Tanya Applegate, Jason Grebely, Laurence Maire, Philippa Marks, Gregory J. Dore, Gail V. Matthews – 17 September 2016 – While interferon‐based therapy has excellent efficacy in acute and recent hepatitis C virus (HCV) infection, the side effect profile limits implementation. Sofosbuvir and ribavirin for 12‐24 weeks is safe and well tolerated in chronic HCV, with efficacy dependent on genotype and disease stage.

Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values

Salvatore Petta, Vincent Wai‐Sun Wong, Calogero Cammà, Jean‐Baptiste Hiriart, Grace Lai‐Hung Wong, Fabio Marra, Julien Vergniol, Anthony Wing‐Hung Chan, Vito Di Marco, Wassil Merrouche, Henry Lik‐Yuen Chan, Marco Barbara, Brigitte Le‐Bail, Umberto Arena, Antonio Craxì, Victor de Ledinghen – 17 September 2016 – Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD).

Subscribe to